Results of a Phase I Placebo-Controlled Trial in Healthy Volunteers to Examine the Safety, Tolerability and PK of the HCV Protease Inhibitor TMC435350 after Single and Repeated Dosing

2007

t max, hour* 5.0 (3.0 - 6.0) 5.0 (4.0 - 6.0) 6.0 (4.0 - 6.0) 6.0 (4.0 - 6.0) 6.0 (4.0 - 6.0) 6.0 (4.0 - 6.0)

Keywords:

References

Citations